Unknown

Dataset Information

0

Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus-uninfected Individuals in HPTN 077.

ABSTRACT: Studies in human immunodeficiency virus (HIV)-infected individuals suggest excess weight gain with integrase inhibitor-based antiretroviral therapy. The HIV Prevention Trials Network Study 077 evaluated changes in weight and fasting metabolic parameters in HIV-uninfected individuals randomized to cabotegravir or a placebo. No differences between arms were found for change in weight or fasting metabolic parameters overall or for subgroups.

SUBMITTER: Landovitz RJ 

PROVIDER: S-EPMC6938971 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus-uninfected Individuals in HPTN 077.

Landovitz Raphael J RJ   Zangeneh Sahar Z SZ   Chau Gordon G   Grinsztejn Beatriz B   Eron Joseph J JJ   Dawood Halima H   Magnus Manya M   Liu Albert Y AY   Panchia Ravindre R   Hosseinipour Mina C MC   Kofron Ryan R   Margolis David A DA   Rinehart Alex A   Adeyeye Adeola A   Burns David D   McCauley Marybeth M   Cohen Myron S MS   Currier Judith S JS  

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20200101 2

Studies in human immunodeficiency virus (HIV)-infected individuals suggest excess weight gain with integrase inhibitor-based antiretroviral therapy. The HIV Prevention Trials Network Study 077 evaluated changes in weight and fasting metabolic parameters in HIV-uninfected individuals randomized to cabotegravir or a placebo. No differences between arms were found for change in weight or fasting metabolic parameters overall or for subgroups. ...[more]

Similar Datasets

Unknown Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077.
| S-EPMC7423859 | biostudies-literature
Unknown Brief Report: Hormonal Contraception Use and Cabotegravir Pharmacokinetics in HIV-Uninfected Women Enrolled in HPTN 077.
| S-EPMC7549535 | biostudies-literature
Unknown Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.
| S-EPMC6224042 | biostudies-literature
Unknown Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial.
| S-EPMC7859863 | biostudies-literature
Unknown Postpartum obesity and weight gain among human immunodeficiency virus-infected and human immunodeficiency virus-uninfected women in South Africa.
| S-EPMC7296802 | biostudies-literature
Unknown Weight Gain and Incident Diabetes Among HIV-Infected Veterans Initiating Antiretroviral Therapy Compared With Uninfected Individuals.
| S-EPMC5023454 | biostudies-literature
Unknown Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084.
| S-EPMC9113509 | biostudies-literature
Unknown Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.
| S-EPMC8599849 | biostudies-literature
Unknown Newborn Hearing Screenings in Human Immunodeficiency Virus-Exposed Uninfected Infants.
| S-EPMC5407375 | biostudies-literature
Unknown Should gestational weight gain charts exclude individuals with excess postpartum weight retention?
| S-EPMC11771746 | biostudies-literature